Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective-Reference-Cited by-同舟云学术

Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective

Published:2012-04-15 Issue:5 Volume:27 Page:651-655
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov. Disord.

Author:

Streffer Johannes R.,Grachev Igor D.,Fitzer-Attas Cheryl,Gomez-Mancilla Baltazar,Boroojerdi Babak,Bronzova Juliana,Ostrowitzki Susanne,Victor Stephen J.,Fontoura Paulo,Alexander Robert

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference22 articles.

1. Neuroprotection in Parkinson's disease: an elusive goal;Biglan;Semin Neurol,2007

2. Striatonigral degeneration. A clinicopathological study;Fearnley;Brain,1990

3. Central nervous system atrophy and clinical status in multiple sclerosis;Zivadinov;J Neuroimaging,2004

4. A double-blind, delayed-start trial of rasagiline in Parkinson's disease;Olanow;N Engl J Med,2009

5. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease;Tetrud;Science,1989

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing;2024-07-28

2. Early detection of Parkinson’s disease through enriching the electronic health record using a biomedical knowledge graph;Frontiers in Medicine;2023-05-12

3. Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features;npj Parkinson's Disease;2021-09-24

4. Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐up;Movement Disorders;2020-07-13

5. Maximising information on smell, quantitative motor impairment and probable REM-sleep behaviour disorder in the prediction of Parkinson’s disease;2020-03-06